Literature DB >> 27928004

Effect of HIV-1 Env on SERINC5 Antagonism.

Saina Beitari1,2, Shilei Ding3, Qinghua Pan1, Andrés Finzi2,3, Chen Liang4,2,5.   

Abstract

SERINC5 is able to restrict HIV-1 infection by drastically impairing the infectivity of viral particles. Studies have shown that the HIV-1 Nef protein counters SERINC5 through downregulating SERINC5 from the cell surface and preventing the virion incorporation of SERINC5. In addition, the Env proteins of some HIV-1 strains can also overcome SERINC5 inhibition. However, it is unclear how HIV-1 Env does so and why HIV-1 has two mechanisms to resist SERINC5 inhibition. The results of this study show that neither Env nor Nef prevents high levels of ectopic SERINC5 from being incorporated into HIV-1 particles, except that Env, but not Nef, is able to resist inhibition by virion-associated SERINC5. Testing of a panel of HIV-1 Env proteins from different subtypes revealed a high frequency of SERINC5-resistant Envs. Interestingly, although the SERINC5-bearing viruses were not inhibited by SERINC5 itself, they became more sensitive to the CCR5 inhibitor maraviroc and some neutralizing antibodies than the SERINC5-free viruses, which suggests a possible influence of SERINC5 on Env function. We conclude that HIV-1 Env is able to overcome SERINC5 without preventing SERINC5 virion incorporation. IMPORTANCE: HIV-1 Nef is known to enhance the infectivity of HIV-1 particles and to contribute to the maintenance of high viral loads in patients. However, the underlying molecular mechanism remained elusive until the recent discovery of the antiviral activity of SERINC5. SERINC5 profoundly inhibits HIV-1 but is antagonized by Nef, which prevents the incorporation of SERINC5 into viral particles. Here, we show that HIV-1 Env, but not Nef, is able to resist high levels of SERINC5 without excluding SERINC5 from incorporation into viral particles. However, the virion-associated SERINC5 renders HIV-1 more sensitive to some broadly neutralizing antibodies. It is possible that, under the pressure of some neutralizing antibodies in vivo, HIV-1 needs Nef to remove SERINC5 from viral particles, even though viral Env is able to resist virion-associated SERINC5.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Env; Nef; SERINC5; human immunodeficiency virus

Mesh:

Substances:

Year:  2017        PMID: 27928004      PMCID: PMC5286904          DOI: 10.1128/JVI.02214-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

2.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

3.  Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS.

Authors:  S Carl; T C Greenough; M Krumbiegel; M Greenberg; J Skowronski; J L Sullivan; F Kirchhoff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

5.  Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis.

Authors:  Madoka Inuzuka; Minako Hayakawa; Tatsuya Ingi
Journal:  J Biol Chem       Date:  2005-08-24       Impact factor: 5.157

6.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Authors:  Brandon F Keele; Elena E Giorgi; Jesus F Salazar-Gonzalez; Julie M Decker; Kimmy T Pham; Maria G Salazar; Chuanxi Sun; Truman Grayson; Shuyi Wang; Hui Li; Xiping Wei; Chunlai Jiang; Jennifer L Kirchherr; Feng Gao; Jeffery A Anderson; Li-Hua Ping; Ronald Swanstrom; Georgia D Tomaras; William A Blattner; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Myron S Cohen; David C Montefiori; Barton F Haynes; Brian Gaschen; Gayathri S Athreya; Ha Y Lee; Natasha Wood; Cathal Seoighe; Alan S Perelson; Tanmoy Bhattacharya; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

8.  Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection.

Authors:  E O Freed; G Englund; M A Martin
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

10.  SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef.

Authors:  Yoshiko Usami; Yuanfei Wu; Heinrich G Göttlinger
Journal:  Nature       Date:  2015-09-30       Impact factor: 49.962

View more
  41 in total

1.  TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins.

Authors:  Minghua Li; Abdul A Waheed; Jingyou Yu; Cong Zeng; Hui-Yu Chen; Yi-Min Zheng; Amin Feizpour; Björn M Reinhard; Suryaram Gummuluru; Steven Lin; Eric O Freed; Shan-Lu Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-06       Impact factor: 11.205

2.  CD4 Expression and Env Conformation Are Critical for HIV-1 Restriction by SERINC5.

Authors:  Xihe Zhang; Jing Shi; Xusheng Qiu; Qingqing Chai; Dylan A Frabutt; Richard C Schwartz; Yong-Hui Zheng
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

Review 3.  Exposing HIV's weaknesses.

Authors:  Philip R Tedbury; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

4.  SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.

Authors:  Chetan Sood; Mariana Marin; Ajit Chande; Massimo Pizzato; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2017-02-08       Impact factor: 5.157

5.  Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection.

Authors:  Saina Beitari; Qinghua Pan; Andrés Finzi; Chen Liang
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

6.  SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.

Authors:  Austin Featherstone; Christopher Aiken
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

7.  Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.

Authors:  Tyler Milston Renner; Kasandra Bélanger; Cindy Lam; María Carla Rosales Gerpe; Joanne Eileen McBane; Marc-André Langlois
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

8.  Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5.

Authors:  Isabelle Staropoli; Jérémy Dufloo; Olivier Schwartz; Nicoletta Casartelli; Anaïs Ducher; Pierre-Henri Commere; Anna Sartori-Rupp; Sophie Novault; Timothée Bruel; Valérie Lorin; Hugo Mouquet
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

9.  An N-Glycosylated Form of SERINC5 Is Specifically Incorporated into HIV-1 Virions.

Authors:  Shilpi Sharma; Mary K Lewinski; John Guatelli
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

Review 10.  Multifaceted Roles of TIM-Family Proteins in Virus-Host Interactions.

Authors:  John P Evans; Shan-Lu Liu
Journal:  Trends Microbiol       Date:  2019-11-12       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.